Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 7/20 | 0.58 |
| ▸ | HTT | P42858 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29671250 | 0.92 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1KMT2ALMNAHTT | |
| SCHEMBL6678841 | 0.92 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1KMT2ALMNAHTT | |
| SCHEMBL6678255 | 0.88 | SHMT2 (0.57) | SMN1; SMN2MEN1KMT2ALMNAHTT | |
| SCHEMBL6675713 | 0.88 | LMNA (0.57) | SMN1; SMN2MEN1KMT2ALMNAHTT | |
| SCHEMBL6678348 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1KMT2ALMNAHTT | |
| SCHEMBL6680310 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2ALMNAHTT | |
| SCHEMBL6674362 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2MEN1KMT2ALMNAHTT | |
| SCHEMBL6678250 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1KMT2ALMNAHTT | |
| SCHEMBL6680684 | 0.83 | FABP4 (0.56) | SMN1; SMN2MEN1KMT2ALMNAHTT | |
| SCHEMBL6680695 | 0.83 | LMNA (0.70) | SMN1; SMN2MEN1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | claimed |
| EP-1005453-B1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS | TULARIK INC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6388131-B2 | Benzenesulfonamide compounds, which encompasses the compound batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene) | TULARIK, INC. | 2002-05-14 | — | — | US | disclosed |
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | disclosed |
| US-6284923-B1 | BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS | TULARIK INC | 2001-09-04 | — | — | US | disclosed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | SMN1; SMN2 4446/4885MEN1 2231/4885KMT2A 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.